Ausgabe 1/2021
Inhalt (18 Artikel)
Use of cucurbitacins for lung cancer research and therapy
Min Liu, Qijia Yan, Bi Peng, Yuan Cai, Shuangshuang Zeng, Zhijie Xu, Yuanliang Yan, Zhicheng Gong
Cardiovascular toxicity of breast cancer treatment: an update
Christos Papageorgiou, Angeliki Andrikopoulou, Meletios-Athanasios Dimopoulos, Flora Zagouri
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
Fred Saad, Kim N. Chi, Neal D. Shore, Julie N. Graff, Edwin M. Posadas, Jean-Baptiste Lattouf, Byron M. Espina, Eugene Zhu, Alex Yu, Anasuya Hazra, Marc De Meulder, Rao N. V. S. Mamidi, Branislav Bradic, Peter Francis, Vinny Hayreh, Arash Rezazadeh Kalebasty
Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study
Michael Michael, Winston Liauw, Sue-Anne McLachlan, Emma Link, Annetta Matera, Michael Thompson, Michael Jefford, Rod J. Hicks, Carleen Cullinane, Athena Hatzimihalis, Ian G. Campbell, Simone Rowley, Phillip J. Beale, Christos S. Karapetis, Timothy Price, Mathew E. Burge
Dynamics of leucocyte DNA thioguanine nucleotide levels during maintenance therapy of childhood acute lymphoblastic leukemia
Rikke Hebo Larsen, Lisa Lyngsie Hjalgrim, Matilda Degn, Jacob Nersting, Bodil Als-Nielsen, Kathrine Grell, Kjeld Schmiegelow
Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
Norihiko Sugisawa, Takashi Higuchi, Qinghong Han, Chihiro Hozumi, Jun Yamamoto, Yoshihiko Tashiro, Hiroto Nishino, Kei Kawaguchi, Michael Bouvet, Takuya Murata, Michiaki Unno, Robert M. Hoffman
Selinexor population pharmacokinetic and exposure–response analyses to support dose optimization in patients with diffuse large B-cell lymphoma
Hongmei Xu, Hanbin Li, Russ Wada, Justin C. Bader, Shijie Tang, Jatin Shah, Sharon Shacham
The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study
Song Mu, Chester Lin, Anna Skrzypczyk-Ostaszewicz, Iurie Bulat, Marina Maglakelidze, Viera Skarbova, Claudia Andreu-Vieyra, Srikumar Sahasranaman
Changes in expression of lysosomal membrane proteins in leucocytes of cancer patients treated with tyrosine kinase inhibitors
N. Pastvova, J. Havlasek, P. Dolezel, K. Kikalova, H. Studentova, A. Zemankova, B. Melichar, P. Mlejnek
Phase I study of tamibarotene monotherapy in pediatric and young adult patients with recurrent/refractory solid tumors
Chika Nitani, Junichi Hara, Hiroshi Kawamoto, Tomoaki Taguchi, Toshimi Kimura, Kenichi Yoshimura, Akinobu Hamada, Shigehisa Kitano, Naoko Hattori, Toshikazu Ushijima, Hiromi Ono, Masako Nakamoto, Tsukiko Higuchi, Akihiro Sato
Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma
Shozo Mori, Taku Aoki, Yuhki Sakuraoka, Takayuki Shimizu, Takamune Yamaguchi, Kyung-Hwa Park, Takatsugu Matsumoto, Takayuki Shiraki, Yukihiro Iso, Keiichi Kubota
Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy
Mohamed A. Mahrous, Gamal A. El-Azab, Hisham A. Tawfik
Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2– advanced breast cancer in Chinese women
Binghe Xu, Huiping Li, Qingyuan Zhang, Wan Sun, Yanke Yu, Wei Li, Shusen Wang, Ning Liao, Peng Shen, Yuan Liu, Yaling Huang, Carlos Linn, Huadong Zhao, John Jiang, Diane Wang
Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma
Chiung-Chi Cheng, Wei-Ting Chao, Jing-Hao Shih, Yih-Shyong Lai, Yung-Hsiang Hsu, Yi-Hsiang Liu
Upregulation of TRIB2 by Wnt/β-catenin activation in BRAFV600E papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib
Nianxue Wang, Jing Wen, Wei Ren, Yuting Wu, Chaonan Deng
Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report
Emmy Boerrigter, Thomas Havenith, Nielka P. van Erp, John-John B. Schnog
Correction to: Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
Yoriko Yamashita‑Kashima, Sei Shu, Masahiro Osada, Takaaki Fujimura, Shigeki Yoshiura, Naoki Harada, Yasushi Yoshimura
Correction to: Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance
Melanie White-Koning, Marie Noëlle Paludetto, Félicien Le Louedec, Laurence Gladieff, Christine Chevreau, Etienne Chatelut, Florent Puisset